Rubric Capital Management LP Takes Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Rubric Capital Management LP acquired a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $139,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after acquiring an additional 58,866 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Zevra Therapeutics during the 1st quarter worth approximately $64,000. Jacobs Levy Equity Management Inc. raised its stake in shares of Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after buying an additional 17,557 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Zevra Therapeutics by 10.7% in the second quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after buying an additional 21,231 shares during the period. Finally, Rhumbline Advisers grew its holdings in Zevra Therapeutics by 17.9% during the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after acquiring an additional 8,619 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Analyst Upgrades and Downgrades

ZVRA has been the subject of a number of recent analyst reports. JMP Securities started coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Guggenheim assumed coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 price objective on the stock. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Roth Mkm upped their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Finally, William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Trading Down 0.6 %

NASDAQ:ZVRA opened at $9.43 on Wednesday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a market cap of $503.37 million, a P/E ratio of -4.79 and a beta of 1.93. The business has a 50 day moving average price of $8.26 and a two-hundred day moving average price of $6.72.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same period in the prior year, the firm posted ($0.40) EPS. As a group, analysts expect that Zevra Therapeutics, Inc. will post -1.96 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.